Icotrokinra
Sponsors
Janssen Cilag International, Janssen Research & Development, LLC
Conditions
Arthritis, PsoriaticColitis, UlcerativeCrohn DiseaseModerately to Severely Active Crohn's DiseaseModerately to Severely Active Ulcerative Colitis
Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RecruitingNCT07196722
Start: 2025-10-03End: 2032-10-06Target: 1092Updated: 2026-03-12
A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
RecruitingCTIS2025-521382-27-00
Start: 2025-12-04Target: 433Updated: 2025-12-08
Phase 3
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
RecruitingNCT06807424
Start: 2025-01-09End: 2028-10-18Target: 750Updated: 2026-03-13
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
Active, not recruitingNCT06878404
Start: 2025-02-21End: 2028-11-21Updated: 2026-03-13
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingNCT07196748
Start: 2025-10-01End: 2032-01-13Target: 882Updated: 2026-02-25
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
RecruitingCTIS2025-521381-10-00
Start: 2025-12-03Target: 391Updated: 2025-12-08